Two cases of viral re-suppression after M184V + R263 K selection on DTG/3TC without treatment modification

Axel Ursenbach; Yvon Ruch; Baptiste Hoellinger; Anne Fuchs; Stéphanie Caspar; Frédérick Jegou; David Rey; Samira Fafi-Kremer; Thibault Mesplede; Pierre Gantner

doi:10.1093/cid/ciae006

Two cases of viral re-suppression after M184V + R263 K selection on DTG/3TC without treatment modification

Clin Infect Dis. 2024 Jan 9:ciae006. doi: 10.1093/cid/ciae006. Online ahead of print.

Authors

Affiliations

¹ Le Trait d'Union, HIV-Infection Care Center, Strasbourg University Hospital, Strasbourg, France.
² Infectious Diseases department, Strasbourg University Hospital, Strasbourg, France.
³ Clinical Virology Laboratory, Strasbourg University Hospital, Strasbourg, France.
⁴ INSERM UMR_S1109, Strasbourg University, Strasbourg, France.
⁵ Viroscience Department, Erasmus Medical Center, Rotterdam, The Netherlands.

PMID: 38193816
DOI: 10.1093/cid/ciae006

Abstract

DTG/3TC has a high genetic barrier against the development of HIV drug resistance. We report two cases of R263K + M184 V mutations during DTG/3TC failure followed by viral suppression after adherence intervention without treatment change that we attribute to residual drug activity, reduced viral fitness, and robust immune competence.

Keywords: Dolutegravir; HIV; M184 V; R263 K; Resistance; lamivudine.